Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

58.49 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,224
Open 58.49
Bid (Size) 58.00 (200)
Ask (Size) 59.50 (100)
Prev. Close 58.49
Today's Range 58.49 - 58.49
52wk Range 33.76 - 59.72
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B ↗
Exelixis (NASDAQ:EXEL) President and CEO Michael Morrissey said the company is focused on expanding its oncology franchises through internal development, selective business development and potential... 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle ↗
Exelixis (NASDAQ:EXEL) executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza, in colorectal cancer later this year.... 
Via MarketBeat

Performance

YTD
+34.2%
+34.2%
1 Month
+10.1%
+10.1%
3 Month
+12.7%
+12.7%
6 Month
+41.8%
+41.8%
1 Year
+44.6%
+44.6%

More News

Read More
News headline image
Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises ↗
Via MarketBeat
Topics Artificial Intelligence
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
From Exelixis, Inc.
Via Business Wire
Exelixis (NASDAQ:EXEL): A Value Stock Backed by Strong Fundamentals ↗
Via Chartmill
Exelixis (NASDAQ:EXEL) Shows Strong Breakout Setup with Perfect Technical Rating ↗
Via Chartmill
Exelixis (NASDAQ:EXEL) Posts Mixed Q2: EPS Beats, Revenue Misses, Guidance Lowered ↗
Via Chartmill
News headline image
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
From Exelixis, Inc.
Via Business Wire
News headline image
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Exelixis (EXEL) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
Exelixis Inc. (NASDAQ:EXEL): A Decent Value Play in the Biotechnology Sector ↗
Via Chartmill
Exelixis Inc (NASDAQ:EXEL) Offers Decent Value with Strong Profitability and Financial Health ↗
Via Chartmill
News headline image
EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Exelixis Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead ↗
Via The Motley Fool
Topics Economy
News headline image
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
3 Under-the-Radar Stocks to Buy and Hold ↗
Via The Motley Fool
News headline image
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near ↗
Via MarketBeat
News headline image
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
From Exelixis, Inc.
Via Business Wire
News headline image
GlobeFlex Exits NCR Atleos After Brink’s Buyout Deal ↗
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Exelixis, Inc. - Common Stock publicly traded?
Yes, Exelixis, Inc. - Common Stock is publicly traded.
What exchange does Exelixis, Inc. - Common Stock trade on?
Exelixis, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Exelixis, Inc. - Common Stock?
The ticker symbol for Exelixis, Inc. - Common Stock is EXEL on the Nasdaq Stock Market
What is the current price of Exelixis, Inc. - Common Stock?
The current price of Exelixis, Inc. - Common Stock is 58.49
When was Exelixis, Inc. - Common Stock last traded?
The last trade of Exelixis, Inc. - Common Stock was at 09/17/26 04:00 PM ET
What is the market capitalization of Exelixis, Inc. - Common Stock?
The market capitalization of Exelixis, Inc. - Common Stock is 18.43B
How many shares of Exelixis, Inc. - Common Stock are outstanding?
Exelixis, Inc. - Common Stock has 18B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.